PMID- 32194036
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20231113
IS  - 1090-2422 (Electronic)
IS  - 0014-4827 (Print)
IS  - 0014-4827 (Linking)
VI  - 390
IP  - 2
DP  - 2020 May 15
TI  - HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration.
PG  - 111960
LID - S0014-4827(20)30168-3 [pii]
LID - 10.1016/j.yexcr.2020.111960 [doi]
AB  - Human leukocyte antigen (HLA) class I molecules present antigenic peptides to 
      cytotoxic T cells, causing lysis of malignant cells. Transplantation biology 
      studies have implicated HLA class I molecules in cell migration, but there has 
      been little evidence presented that they influence cancer cell migration, a 
      contributing factor in metastasis. In this study, we examined the effect of HLA-B 
      on pancreatic cancer cell migration. HLA-B siRNA transfection increased the 
      migration of the S2-013 pancreatic cancer cells but, in contrast, reduced 
      migration of the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines. Integrin 
      molecules have previously been implicated in the upregulation of pancreatic 
      cancer cell migration, and knockdown of HLA-B in S2-013 cells heightened the 
      expression of integrin beta 1 (ITGB1), but in the PANC-1 and MIA PaCa-2 cells 
      HLA-B knockdown diminished ITGB1 expression. A transmembrane sequence in an 
      S2-013 HLA-B heavy chain matches a corresponding sequence in HLA-B in the BxPC-3 
      pancreatic cancer cell line, and knockdown of BxPC-3 HLA-B mimics the effect of 
      S2-013 HLA-B knockdown on migration. In total, our findings indicate that HLA-B 
      influences the expression of ITGB1 in pancreatic cancer cells, with concurrent 
      distinctions in transmembrane sequences and effects on the migration of the 
      cells.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Sliker, Bailee H
AU  - Sliker BH
AD  - Eppley Institute for Research in Cancer and Allied Diseases and the Fred and 
      Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 
      USA.
FAU - Goetz, Benjamin T
AU  - Goetz BT
AD  - Eppley Institute for Research in Cancer and Allied Diseases and the Fred and 
      Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 
      USA.
FAU - Barnes, Raina
AU  - Barnes R
AD  - Eppley Institute for Research in Cancer and Allied Diseases and the Fred and 
      Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 
      USA.
FAU - King, Hannah
AU  - King H
AD  - Eppley Institute for Research in Cancer and Allied Diseases and the Fred and 
      Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 
      USA.
FAU - Maurer, H Carlo
AU  - Maurer HC
AD  - Columbia University Department of Medicine and the Herbert Irving Comprehensive 
      Cancer Center, Columbia University Medical Center, New York, NY, USA.
FAU - Olive, Kenneth P
AU  - Olive KP
AD  - Columbia University Department of Medicine and the Herbert Irving Comprehensive 
      Cancer Center, Columbia University Medical Center, New York, NY, USA.
FAU - Solheim, Joyce C
AU  - Solheim JC
AD  - Eppley Institute for Research in Cancer and Allied Diseases and the Fred and 
      Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 
      USA; Department of Pathology and Microbiology, University of Nebraska Medical 
      Center, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, 
      University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: 
      jsolheim@unmc.edu.
LA  - eng
GR  - P50 CA127297/CA/NCI NIH HHS/United States
GR  - R21 CA223429/CA/NCI NIH HHS/United States
GR  - P30 CA036727/CA/NCI NIH HHS/United States
GR  - T32 CA009476/CA/NCI NIH HHS/United States
GR  - T32 CA009035/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200316
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (HLA-B Antigens)
RN  - 0 (ITGA2B protein, human)
RN  - 0 (Integrin alpha2)
RN  - 0 (Integrin beta1)
RN  - 0 (Itgb1 protein, human)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.10.2 (Focal Adhesion Kinase 1)
RN  - EC 2.7.10.2 (PTK2 protein, human)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Movement/*genetics
MH  - Cell Proliferation
MH  - Focal Adhesion Kinase 1/genetics/metabolism
MH  - *Gene Expression Regulation, Neoplastic
MH  - HLA-B Antigens/*genetics/metabolism
MH  - Humans
MH  - Integrin alpha2/genetics/metabolism
MH  - Integrin beta1/*genetics/metabolism
MH  - Organ Specificity
MH  - Pancreas/*metabolism/pathology
MH  - Protein Isoforms/antagonists & inhibitors/genetics/metabolism
MH  - RNA, Small Interfering/genetics/metabolism
MH  - Signal Transduction
PMC - PMC7182497
MID - NIHMS1578623
OTO - NOTNLM
OT  - HLA
OT  - Integrin
OT  - Major histocompatibility complex class I
OT  - Migration
OT  - Pancreatic cancer
COIS- Declaration of competing interest The authors declare that there are no conflicts 
      of interest.
EDAT- 2020/03/21 06:00
MHDA- 2020/12/15 06:00
PMCR- 2021/05/15
CRDT- 2020/03/21 06:00
PHST- 2019/10/25 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/03/21 06:00 [entrez]
PHST- 2021/05/15 00:00 [pmc-release]
AID - S0014-4827(20)30168-3 [pii]
AID - 10.1016/j.yexcr.2020.111960 [doi]
PST - ppublish
SO  - Exp Cell Res. 2020 May 15;390(2):111960. doi: 10.1016/j.yexcr.2020.111960. Epub 
      2020 Mar 16.